Active surveillance is evolving as a management strategy for favorable-risk prostate cancer. Further study is needed to determine the safety of surveillance for specific subgroups of patients, and to clarify the role of genomic markers and image-guided biopsy.
European urology. 2016 Jul 22 [Epub ahead of print]
H Ballentine Carter
The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: .